
SOPH Stock Forecast & Price Target
SOPH Analyst Ratings
Bulls say
Sophia Genetics is an innovative healthcare technology company using AI in diagnostics to support oncology and rare diseases. They have a decentralized model and strategic partnerships, which are key drivers for future growth. With a projected market value of $40B and a focus on the US market, the company has a strong global presence and a robust data network that generates recurring revenue. Additionally, Sophia Genetics has a strong cash position and is expected to achieve profitability in the medium term, making it a promising investment opportunity for those with a positive outlook on the company's future.
Bears say
Sophia Genetics is facing fierce competition in the growing field of AI-based precision medicine, with centralized testing providers, platform players, and sequencer manufacturers all vying for market share. Additionally, the company's heavy focus on data has resulted in significant cybersecurity risks and a potential reliance on patents licensed from third parties. In spite of strong growth metrics, the company remains unprofitable and faces uncertainty in achieving profitability in the near future. The company's high valuation multiples and reliance on future revenue growth make it a risky investment.
This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.
SOPH Analyst Forecast & Price Prediction
Start investing in SOPH
Order type
Buy in
Order amount
Est. shares
0 shares